Plot­ting to be the Bridge­Bio of AI, Atom­wise lands $123 mil­lion Se­ries B for hype-heavy plat­form

The PR-friend­ly, well-part­nered AI biotech that’s pro­voked stern skep­ti­cism in some sci­en­tif­ic cor­ners is get­ting a boat­load of new cash.

Atom­wise has an­nounced a $123 mil­lion Se­ries B round led by San­abil In­vest­ments — a sub­sidiary of the Sau­di roy­al fund — and B Cap­i­tal Group and joined by DCVC and Y Com­bi­na­tor, among oth­ers. The new round is near­ly triple what Atom­wise had raised pri­or and will go to­wards both scal­ing their mol­e­cule-hunt­ing soft­ware and build­ing the grow­ing net­work of spin­outs they’re launch­ing to de­vel­op some of the mol­e­cules that soft­ware has turned up.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER